Neutrophils and their Fcγ receptors are essential in a mouse model of transfusion-related acute lung injury

Mark R. Looney, … , Clifford A. Lowell, Michael A. Matthay


Transfusion-related acute lung injury (TRALI) is the most common cause of transfusion-related mortality. To explore the pathogenesis of TRALI, we developed an in vivo mouse model based on the passive transfusion of an MHC class I (MHC I) mAb (H2Kd) to mice with the cognate antigen. Transfusion of the MHC I mAb to BALB/c mice produced acute lung injury with increased excess lung water, increased lung vascular and lung epithelial permeability to protein, and decreased alveolar fluid clearance. There was 50% mortality at a 2-hour time point after Ab administration. Pulmonary histology and immunohistochemistry revealed prominent neutrophil sequestration in the lung microvasculature that occurred concomitantly with acute peripheral blood neutropenia, all within 2 hours of administration of the mAb. Depletion of neutrophils by injection of anti-granulocyte mAb Gr-1 protected mice from lung injury following MHC I mAb challenge. FcRγ−/− mice were resistant to MHC I mAb–induced lung injury, while adoptive transfer of wild-type neutrophils into the FcRγ−/− animals restored lung injury following MHC I mAb challenge. In conclusion, in a clinically relevant in vivo mouse model of TRALI using an MHC I mAb, the mechanism of lung injury was dependent on neutrophils and their Fcγ receptors.

Find the latest version:

http://jci.me/27238-pdf
Neutrophils and their Fcγ receptors are essential in a mouse model of transfusion-related acute lung injury

Mark R. Looney,1,2 Xiaol Su,1 Jessica A. Van Ziffle,3 Clifford A. Lowell,3 and Michael A. Matthay1,2,4
1Cardiovascular Research Institute, 2Department of Medicine, 3Department of Laboratory Medicine, and 4Department of Anesthesia, UCSF, San Francisco, California, USA.

Introduction
Transfusion-related acute lung injury (TRALI) is the most common cause of transfusion-related mortality. To explore the pathogenesis of TRALI, we developed an in vivo mouse model based on the passive transfusion of an MHC class I (MHC I) mAb (H2Kd) to mice with the cognate antigen. Transfusion of the MHC I mAb to BALB/c mice produced acute lung injury with increased excess lung water, increased lung vascular and lung epithelial permeability to protein, and decreased alveolar fluid clearance. There was 50% mortality at a 2-hour time point after Ab administration. Pulmonary histology and immunohistochemistry revealed prominent neutrophil sequestration in the lung microvasculature that occurred concomitantly with acute peripheral blood neutropenia, all within 2 hours of administration of the mAb. Depletion of neutrophils by injection of anti-granulocyte mAb Gr-1 protected mice from lung injury following MHC I mAb challenge. FcRγ−/− mice were resistant to MHC I mAb–induced lung injury, while adoptive transfer of wild-type neutrophils into the FcRγ−/− animals restored lung injury following MHC I mAb challenge. In conclusion, in a clinically relevant in vivo mouse model of TRALI using an MHC I mAb, the mechanism of lung injury was dependent on neutrophils and their Fcγ receptors.

Results
MHC I mAb produces ALI in mice. Wild-type BALB/c mice were selected to receive the MHC I mAb (anti-H2Kd), since this mouse strain expresses H2Kd. BALB/c congenic (BALB/K) mice, which have a H2Kd MHC I locus, were used as controls. An additional control was an isotype-matched mAb (IgG2a, κ) with unknown antigen specificity. All mice received an equal-volume i.v. injection. MHC I mAb–treated BALB/c mice developed a sharp increase in lung water at 2 hours after i.v. challenge (Figure 1A). In contrast, the BALB/K animals failed to show evidence of pulmonary vascular leak following injection of anti-H2Kd, confirming that the disease was caused by recognition of the d allotype of MHC I protein in normal BALB/c mice. In addition, the isotype-matched mAb given to BALB/c mice did not produce an increase in lung water. The increase in extravascular lung water in BALB/c MHC I mAb–treated mice observed in Figure 1A was matched by the increase in lung vascular permeability to protein (125I-labeled albumin; Figure 1B). An MHC I mAb dose-response curve was determined, and a dose of 4.5 mg/kg produced the most reproducible lung injury (data not shown). Since the isotype-matched mAb–treated mice and the BALB/K mice challenged with MHC I mAb develop no lung injury, in other experiments in this study, PBS delivered to wild-type BALB/c mice was used as the control.

Nonstandard abbreviations used: ALI, acute lung injury; ARDS, acute respiratory distress syndrome; BAL, bronchoalveolar lavage; BALB/K mouse, BALB/c congenic mouse; EVPE, extravascular plasma equivalents; MHC I, MHC class I; TRALI, transfusion-related acute lung injury.

Conflict of interest: The authors have declared that no conflict of interest exists.

MHC I mAb–challenged mice develop severe pulmonary neutrophil sequestration and peripheral blood neutropenia. Histologic examination of the lungs from MHC I mAb–treated mice revealed obvious septal thickening and severe inflammatory infiltrates within 2 hours after mAb challenge (Figure 4, compare A and B). Most of these inflammatory cells appeared to be granulocytes, many of which plugged branching microvascular vessels within the pulmonary parenchyma (Figure 4C). Animals with obvious clinical evidence of pulmonary edema manifested histologic evidence of intra-alveolar proteinaceous fluid (Figure 4D).

To further clarify the neutrophil sequestration in MHC I mAb–treated mice, we performed immunohistochemistry using the neutrophil-specific mAb Gr-1. This immunohistochemistry confirmed extensive neutrophil sequestration in the lungs 2 hours following MHC I mAb challenge (Figure 5, A and B). Of note, there was only mild neutrophilia (0–5%) in the BAL of MHC I mAb–challenged mice at the early time point of 2 hours (data not shown).

Peripheral blood neutropenia is commonly observed in TRALI patients, potentially due to pulmonary sequestration of circulating cells (2, 18). Similar to the human cases, we also observed acute neutropenia in the MHC I mAb–treated animals (Figure 5C). Thrombocytopenia has also been reported in some cases in the human TRALI literature (19–21), but none was detected in this experimental model (data not shown).

MHC I mAb–treated mice have a selective increase in plasma cytokines and chemokines. Multiplex cytokine analysis revealed significant differences between controls and MHC I mAb–treated mice in 3 cytokines. Two prototypic inflammatory cytokines, TNF-α and IL-6, and an anti-inflammatory cytokine, IL-10, were elevated in MHC I mAb–treated mice (Figure 6A). Plasma levels of IFN-γ,
GM-CSF, IL-1β, IL-2, IL-4, IL-5, and IL-12 were not increased in MHC I mAb–treated mice compared with controls. Since there was histologic evidence of lung neutrophil sequestration in MHC I mAb–challenged mice, plasma and BAL concentrations of the murine IL-8 homologs, KC and macrophage inflammatory protein-2 (MIP-2), were measured. Both KC and MIP-2 levels were increased in the plasma (Figure 6B) and BAL (Figure 6C) of MHC I mAb–challenged mice compared with controls.

**Neutrophil depletion protects mice from MHC I mAb–induced ALI.** Neutrophils are prominent cellular mediators in some animal models of ALI (22), and neutrophil depletion has been shown to be protective in models of lung injury such as acid injury (23) and hemorrhagic shock (24). Given the extensive neutrophil sequestration observed in the lungs of MHC I mAb–treated mice, we hypothesized that neutrophil depletion would protect animals from MHC I mAb–induced lung injury. We used the Gr-1 mAb to selectively deplete mouse neutrophils, as has been previously described (25, 26). Within 24 hours, there was near complete neutrophil depletion in Gr-1 mAb–treated mice (50 ± 35 versus 783 ± 394 neutrophils/ml for Gr-1 mAb and PBS groups, respectively) with preservation of lymphocyte, monocyte, and platelet counts and hemoglobin (data not shown). After confirming neutrophil depletion in the Gr-1 mAb–treated mice, these animals were challenged with MHC I mAb or control. The Gr-1 mAb neutrophil–depleted mice were protected from lung injury, demonstrating lung water and lung vascular permeability values similar to control mice (Figure 7, A and B). We also used a less specific method of neutrophil depletion, i.p. vinblastine, which led to greater than 95% neutrophil depletion at 72 hours. Vinblastine-treated mice were also protected from lung edema formation and lung vascular permeability to protein when challenged with i.v. MHC I mAb (data not shown).

**FcγR−/− mice are protected from MHC I mAb–induced ALI, while adoptive transfer of wild-type and MHC I–deficient neutrophils restores lung injury in FcγR−/− mice following MHC I mAb challenge.** To determine whether Ab-based TRALI involves specific immune recognition of endothelial-bound MHC Abs by neutrophils, we studied FcγR−/− mice, which lack the γ chain subunit of IgG and IgE receptors. FcγR−/− mice lack both the high-affinity FcγRI and low-affinity FcγRII receptors and have been shown to be refractory to stimulatory Fcγ receptor signaling (27). FcγR−/− mice on the BALB/c genetic background were compared with age- and sex-matched wild-type BALB/c mice in the anti–MHC I mAb model. As shown in Figure 8, FcγR−/− mice were completely protected from MHC I mAb–mediated lung injury compared with wild-type controls.

Since FcγRI and FcγRII receptors are present not only on neutrophils but also on lymphocytes, monocytes, mast cells, and dendritic cells, the specific contribution of the Fcγ receptor on neutrophils cannot be inferred from the above experiments. To answer this question, we adoptively transferred (by i.v. injection) wild-type neutrophils (5 × 10⁶ cells) into FcγR−/− mice, then immediately challenged these animals with anti-MHC I mAb. Injection of wild-type neutrophils into FcγR−/− mice restored ALI following MHC I mAb delivery (Figure 8, A and B). Untreated animals showed no evidence of lung injury from the neutrophil transfusion (data not shown). Additionally, when FcγR−/− mice were reconstituted with MHC I–deficient neutrophils (B2m−/−), lung injury was again restored with MHC I mAb challenge, which excludes direct neutrophil activation by binding of the MHC I mAb to the cell surface as a pathogenic event. In summary, these data demonstrate that Fcγ receptors on neutrophils alone are responsible for generation of ALI in this model.

MHC I mAb delivered i.v. binds diffusely to the microvasculature of the lung, liver, and kidney. Using Rag2−/− mice (H2Kd+), which lack endogenous Ig, we tracked the in vivo binding of i.v. MHC I mAb with immunohistochemistry. Of note, Rag2−/− mice challenged with MHC I mAb developed similar lung injury compared with wild-type

---

**Figure 3**
MHC I mAb produces increased alveolar epithelial permeability and decreased alveolar fluid clearance. (A and B) Alveolar epithelial permeability to [⁵¹]labeled albumin (A) and BAL total protein (B) in BALB/c mice given PBS (n = 6) or MHC I mAb (n = 10). **P < 0.01. (C) In situ alveolar fluid clearance was measured over 30 minutes in mice treated with MHC I mAb (n = 7) or PBS (n = 6). *P < 0.05.

**Figure 4**
Lung histology from control and MHC I mAb–treated mice. (A and B) Low-power views of lungs from mice given either control (A) or MHC I mAb (B). In the MHC I mAb–treated mouse, there was increased intra-alveolar neutrophils, septal thickening, and interstitial inflammation. (C) High-power view of lung from a mouse given MHC I mAb. Arrow indicates a branching vessel that is plugged with neutrophils. (D) MHC I mAb–treated mouse with intra-alveolar proteinaceous material. H&E staining. Magnification, ×200 (A and B); ×400 (C and D).
Since neutrophils express MHC I antigen, it was not surprising that wild-type and MHC I–deficient neutrophils (FcRγ–/–) bound MHC I mAb, but MHC I–deficient neutrophils (B2m–/–) did not (Figure 10A). Using a flow cytometry–based neutrophil activation assay, we found there was no evidence of direct activation of neutrophil oxidative burst activity by the MHC I mAb in either wild-type or FcRγ–/– cells (Figure 10B).

**MHC I mAb–mediated ALI is independent of C5a.** Since clinical studies (21) and other animal models of TRALI (8) have implicated complement activation, we used C5aR–/– mice to test the role of complement in the development of MHC I mAb–mediated ALI. When C5aR–/– mice on the BALB/c background were given i.v. MHC I mAb, severe lung injury developed that was no different from lung injury in BALB/c wild-type controls (data not shown). Furthermore, there was approximately 66% mortality in the C5aR–/– mice, which was similar to the approximately 50% mortality observed in BALB/c wild-type mice (Figure 2A).

**Discussion**

The major findings of this study are that (a) the transfusion of an MHC I mAb to mice with the cognate antigen produced ALI and mortality in a clinically relevant time period; (b) the lung edema resulted from a combination of both increased lung vascular and lung epithelial permeability to protein and decreased alveolar fluid clearance, what we believe to be a novel finding in TRALI; and (c) neutrophils and the Fcγ receptors on neutrophils were essential to the pathogenesis of ALI in this mouse model of TRALI.

An important goal of this study was to develop a clinically relevant, reproducible, and robust model of human TRALI. There are several lines of evidence that suggest that this mouse model of TRALI relates well to the human condition. First, our model is based on the transfusion of MHC I Abs, the most frequently isolated Ab in fatal cases of TRALI reported to the FDA in 2001–2003 (6). In addition, there are numerous case reports and case series in the literature that report the association of MHC I Abs with fatal and nonfatal TRALI (2, 5). Second, we selected a 2-hour experimental end point to reflect a time point of injury that is clinically observed in the majority of TRALI cases. The National Heart, Lung, and Blood Institute Consensus definition of TRALI states that the lung injury develops during or within 6 hours of the completion of the blood product transfusion (1). In addition, TRALI most commonly develops within the first 30 minutes to 1 hour after the initiation of blood product transfusion (1, 2). Mice in
our model of TRALI developed lung injury within a 2-hour experimental time point, often within 30 minutes of MHC I mAb injection, and therefore this model is consistent with the time course of clinical TRALI.

Our experimental results of transfusing MHC I mAb to mice also reveal several features that model human TRALI well. First, the lung injury that developed was often severe, with 50% mortality in these unsupported mice at 2 hours. The majority of human TRALI cases require intensive care support and mechanical ventilation, and there is 5–10% mortality (5). Second, the lung injury in our model was characterized by increased lung vascular permeability to protein, the defining characteristic of ALI. Yost (28) and others (29, 30) have reported that the undiluted pulmonary edema fluid of well-characterized patients with TRALI contains a high protein concentration consistent with increased permeability edema. Autopsy studies have also shown proteinaceous edema fluid in patients dying of TRALI (31). Third, we detected peripheral blood neutropenia in MHC I mAb–treated mice, as has been reported in human TRALI (2, 18). Finally, the histologic finding of extensive neutrophil sequestration in the lung microvasculature has also been reported in autopsy reports on TRALI (31).

We have also made what we believe to be novel findings in Ab-mediated TRALI. The existing ex vivo animal models of TRALI have focused on the lung endothelium and indirect measures of capillary permeability. In this MHC I mAb model of TRALI, not only was there increased permeability of the lung endothelium, but there was also a striking increase in lung epithelial permeability with a concomitant impairment in fluid resorptive capacity. We believe the finding that the alveolar epithelium was a target of damage in Ab-mediated TRALI to be novel and to have potential therapeutic implications. Research done by our group and other investigators has found that decreased alveolar fluid transport is a common finding in both experimental ALI (12) and in human patients with ALI and acute respiratory distress syndrome (ARDS) (13, 14). In fact, human patients with ALI/ARDS and impaired alveolar fluid clearance have higher mortality than do ALI/ARDS patients with intact alveolar fluid clearance. It is possible that the presence or absence of impaired alveolar fluid clearance in patients with TRALI could contribute to the clinical outcome in this syndrome—patients with more severe alveolar epithelial injury and impaired fluid clearance would likely have a worse prognosis.

We have made 2 fundamental observations about the pathogenesis of TRALI with this MHC I mAb model: the essential contribution of neutrophils and Fcγ receptor signaling. The role of neutrophils in TRALI was first studied in an isolated, perfused rabbit lung model that used human neutrophils, a human anti-neutrophil Ab implicated in TRALI, and rabbit complement (8). The human neutrophils were essential to the development of lung injury in that model, but there was cross-species contamination. The peripheral blood neutropenia observed in our model and in several reported cases of TRALI also points to neutrophils potentially being sequestered in the lungs of TRALI patients, a hypothesis that was confirmed in our present model with histology and immunohistochemistry. Using 2 methods of neutrophil depletion, we now provide convincing evidence that neutrophils are the essential cellular effectors of lung injury in this mouse model of TRALI.

The factors leading to sequestration of neutrophils in the lung vasculature in TRALI are incompletely understood, but a 2-hit hypothesis has been offered to help explain the development of human and experimental TRALI (7). It is thought that underlying medical conditions (e.g., surgery and infection) prime circulatory neutrophils and potentially lung endothelium, leading to lung neutrophil sequestration and an augmented response to a second challenge (e.g., blood products). The finding of increased
plasma levels of TNF-α

...intensive care unit, patients that received FFP from multip...

...neutrophile transfer into FcγR−/− mice. This contrasts with a recent TRALI model in which an anti-neutrophil mAb directly activated neutrophils in an ex vivo rat lung model (9). We hypothesize that the passively transfused MHC I mAb binds to MHC I antigen present on the pulmonary endothelium, the first vascular bed encountered after injection. The MHC I Ab bound to the lung endothelium sequesters circulating neutrophils via Fcγ receptor interaction, leading to neutrophil activation and lung injury. Elaboration of the neutrophil chemokines KC and MIP-2 probably also contributes to further neutrophil recruitment.

It was interesting to find that C5a receptors were not essential in MHC I mAb-mediated ALI. Some animal models of immune complex alveolitis have shown that C5a is an essential chemokine in recruiting neutrophils into the lung and that it also directly activates neutrophils and endothelial cells (39, 40), although a recent animal model was complement independent (9). Future studies will be needed to completely address the role of complement in this TRALI model.

A limitation of our model of TRALI is that the use of mAbs may not exactly mimic the polyclonal MHC I, II, and anti-neutrophil Abs implicated in human TRALI. Another question in the TRALI literature is the dose or titer of Abs needed to produce TRALI in a recipient, although the presence of a priming condition and host susceptibility may determine this also. Indeed, it is possible that different anti-MHC I or –MHC II Abs would have different capacities to initiate neutrophil activation leading to lung injury. This is supported by our observation that not all anti-MHC I mAbs (all IgG2a, κ) tested were able to induce ALI in BALB/c or C57BL/6j mice (data not shown). Hence in humans with different repertoires of polyclonal anti-MHC Abs, some Abs may be more pathogenic in transfused recipients than others. The issue of what is a pathogenic titer of anti-MHC Abs in a transfusion product will likely remain difficult to quantify.

A potential strength of this model of TRALI is the ability to examine other (non-lung) organ damage from MHC I Ab challenge. We found that our mAb bound diffusely to the liver and kidney microvasculature, and we have preliminary evidence of renal injury at our 2-hour endpoint. Nonpulmonary organ injury is an area that has been neglected in the human TRALI literature as well as in the existing TRALI models, which use isolated lung preparations. The presence or absence of major organ damage from challenge with an Ab against a ubiquitously expressed antigen could reveal new insights into the TRALI syndrome and will be a focus of future experiments.

In conclusion, this in vivo mouse model of TRALI based on MHC I mAb transfusion reproduces several features of human TRALI and helps overcome the limitations of existing TRALI animal models. Lung injury and death in this TRALI model resulted from a combination of lung vascular and lung epithelial permeability and the reduced ability of the alveolar epithelium to remove edema fluid.
Both the vascular endothelial and the alveolar epithelial injury were caused by neutrophil sequestration and activation in the lung through Fcγ receptor interactions with endothelial-bound MHC I Ab. Additional inflammatory mediators produced during the response such as KC, MIP-2, TNF-α, and IL-6 further amplified the inflammation and neutrophil activation. Depletion of neutrophils protected animals from MHC I mAb–induced lung injury, while adoptive transfer experiments indicate that Fcγ receptors on neutrophils were the major receptors that initiated the inflammatory response. The results of these experimental studies suggest a potentially novel therapeutic strategy, targeting Fcγ receptor signaling pathways, that may prove beneficial in limiting lung injury in TRALI.

Methods

Experimental animals. BALB/c wild-type mice were purchased from Charles River Laboratories; BALB/c MHC I congenic mice (BALB/K) were purchased from The Jackson Laboratory, and B2m−/− mice were kindly provided by C. Gerard (Children’s Hospital Boston, Boston, Massachusetts, USA) and M. Anderson (University of California, San Francisco, San Francisco, USA), respectively. All experimental procedures were performed in 8- to 12-week-old male mice and were approved by the University of California, San Francisco Committee on Animal Research.

MHC I mAb production. A hybridoma (34-1-2S) was purchased from the American Type Culture Collection that produces a mAb against H2Kd (IgG2a, κ). The hybridoma was grown in tissue culture medium containing 1% fetal bovine serum and incubated at 37°C and 5% CO2. Hybridoma supernatant was collected and filtered through a 0.2-μm filter. The MHC I mAb was purified using protein A sepharose affinity chromatography and dialyzed overnight in PBS (pH 7.4). The protein concentration of the mAb was spectrophotometrically determined using Bio-Rad protein reagent. The mAb solution (0.5–0.65 mg/ml) was frozen at −80°C until the time of the experiments. For selected experiments, a protein biotinylation kit (Alpha Diagnostic International) was used to generate MHC I–biotin mAb.

Animal preparation and experimental protocol. For MHC I mAb injection, mice were anesthetized with i.p. ketamine (80 mg/kg) and xylazine (12 mg/kg). The mice were placed supine on a warming blanket, and the jugular vein was isolated. Using a 30-gauge sterile needle attached to PE-10 tubing, venous blood was aspirated from the jugular vein to verify intravascular placement of the needle and to remove a sample of blood (~200 μl) for baseline measurements. Mice were given an i.v. volume-matched injection (150–250 μl) of either MHC I mAb (4.5 mg/kg), an isotype-matched mAb (IgG2a, κ; 4.5 mg/kg; BD Biosciences—Pharmingen), or PBS. The skin was sutured with 6-0 silk suture, and the mice were recovered. Mice were euthanized at 2 hours with an i.p. injection of pentobarbital (200 mg/kg).

Measurement of excess lung water and lung vascular permeability. The gravimetric method was used to determine extravascular lung wet wt/dry wt ratios as previously described (15, 41). Briefly, the lungs were removed at the end of the experiment, and the wet weight was recorded. The lungs were then homogenized and dried for greater than 24 hours in a drying oven, at which time the dry weight was recorded. Measurements of the hemoglobin concentration in the lung homogenate allowed for the calculation of the bloodless lung wet wt/dry wt ratio.

For measurements of lung vascular permeability, 125I-labeled albumin (Iso-Tex Diagnostics Inc.) was added to the i.v. instillate. At the end of the experiment, the radioactivity of a blood sample and the whole lungs was determined with a gamma counter (Packard 5000 Series). The ratio of the radioactivity in the blood and in the bloodless lungs was used to calculate the lung vascular permeability to protein and the extravascular plasma equivalents (EVPE) as we have described previously (15, 23).

Alveolar epithelial permeability and BAL. Alveolar epithelial permeability was determined by the leakage of i.v. 125I-labeled albumin into the airspaces of the lung at the end of the experiment. A BAL was performed at the end of the experiment with 1 ml of cold PBS flushed 3 times into the lung through a tracheotomy. The alveolar epithelial permeability was calculated by a ratio of the radioactivity/ml in the BAL and in a blood sample (15). The total protein concentration in the BAL was determined by the Bradford method.
Alveolar fluid clearance measurements. The in situ method for measuring alveolar fluid clearance was used as previously described (42, 43). Briefly, 2 hours after receiving either the MHC I mAb or control (isotype control mAb or PBS), mice were euthanized with i.p. pentobarbital (200 mg/kg) and exsanguinated by transaction of the abdominal aorta. Core temperature was maintained at 37–38°C (measured with a subdiaphragmatic temperature probe) with a warming blanket and infrared lamp. A tracheostomy was performed, and a 20-gauge trimmed angiocath was inserted into the trachea. The lungs were continuously inflated with 5 cm H2O continuous positive airway pressure and 100% O2. The trachea was instilled with 13 ml/kg of a 5% bovine serum albumin and lactated Ringer’s solution. We also added 0.1 μCi 125I-labeled albumin to the instillate as a radio-tracer. One minute after the initial injection, a sample was obtained from the distal airspaces to serve as the baseline sample. At 30 minutes another sample was obtained. The radioactivity of the 1-minute baseline and the 30-minute samples were determined with a gamma counter. The concentration of the 125I-labeled albumin at 30 minutes allowed for the calculation of alveolar fluid clearance.

Measurement of white blood cell count and differential in the blood. A sample of blood was placed in EDTA-coated vials, and a multispecies hematology instrument (Hemavet 950FS; Drew Scientific) was used to generate a complete blood count with cellular differential.

Neutrophil depletion experiments. Vinblastine (2.5 mg/kg, Sigma-Aldrich) was given i.p. to mice, and neutrophil depletion (>95%) was confirmed 24 hours later.

Neutrophil isolation and reconstitution. Wild-type BALB/c mice were euthanized by cervical dislocation, and the bone marrow from the femurs and tibias was flushed with PBS using a 25-gauge needle. The whole bone marrow was centrifuged and washed in PBS, and the red blood cells were incubated with 1.2% NaCl and then filtered over a 70-μm nylon cell strainer (BD Biosciences — Discovery Labware). The solution was centrifuged and resuspended in PBS and then delicately applied over a 62% Percoll gradient. The Percoll solution was centrifuged for 30 minutes at 1,500 g. The neutrophil pellet was then isolated, washed and centrifuged twice, and counted with a Coulter counter (Z1 series; Beckman Coulter). Greater than 90% neutrophil purity was confirmed with a cytopsin preparation (Cytopsin 3; Thermo Electron Corp.) and Diff-Quick staining.

Multiplex cytokine and chemokine analysis. Mouse blood samples were collected in citrated syringes and centrifuged at 1,750 g for 10 minutes, and the plasma fraction was collected and frozen at −80°C. A mouse cytokine multiplex kit (MesoCyto Kine 10-plex; BioSource International) was used to assay for TNF-α, IFN-γ, GM-CSF, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, and IL-12. ELISA kits were used to measure murine KC and MIP-2 in the plasma and BAL (R&D Systems).

Histology and immunohistochemistry. Mice were euthanized with i.p. pentobarbital, and a 20-gauge trimmed angiocath was inserted into the trachea. The lungs were then inflated with air and 4% paraformaldehyde. The trachea was ligated, and the lungs were immersed in 4% paraformaldehyde and embedded in paraffin. In selected experiments, the liver and the right kidney were also removed. Sections (5 μm) were used for routine H&E histology and for immunohistochemistry. Gr-1 mAb was used for neutrophil immunohistochemistry. For MHC I mAb immunohistochemistry, MHC I mAb was injected i.v. into Rag2−/− mice, and the lungs were perfused with PBS via the right ventricle and processed as described above. MHC I mAb was detected in paraffin sections using a goar anti-mouse HRP detection kit (BD Biosciences).

Flow cytometry. Single-cell suspensions were prepared from wild-type, FcRγ−/−, and B2m−/− mouse bone marrow. Aliquots of 1.5 × 106 cells were stained with anti-MHC I-biotin (1 μg/ml in the presence of FeCyRII/III–blocking Ab (2.4G2; BD Biosciences — Pharmingen) and anti–Gr-1–PE Ab (RB6-8C5; BD Biosciences — Pharmingen). Anti–MHC I-biotin was detected using streptavidin-FITC (BD Biosciences — Pharmingen). Neutrophils were gated by Gr-1 positivity and appropriate forward- and side-scatter settings. For in vitro ROS production, whole bone marrow was loaded with 10 μM aminephilen fluororescin (Invitrogen Corp.). MHC I was cross-linked by the addition of 25 μg anti–MHC I-biotin in the presence of FeCyRII/III–blocking Ab, followed by addition of 40 μg streptavidin (Jackson Immunoresearch Laboratories Inc.) and incubation at 37°C for 15, 30, and 60 minutes. ROS was induced by incubating neutrophils with 400 nM PMA (Sigma-Aldrich) as a positive control. Flow cytometric acquisition was performed using FACScan (BD Biosciences), and data were analyzed using FlowJo software (version 6.4.3; Tree Star Inc.).

Statistics. Results are reported as individual data points and as mean ± SD. To determine significance, 2-tailed Student’s t test, ANOVA, and χ2 test were used as appropriate. P values less than or equal to 0.05 were determined to be significant.

Acknowledgments

This work was supported in part by a GlaxoSmithKline Pulmonary Fellowship Award (to M.R. Looney), by a Canadian Institutes of Health Research Doctoral Research Award (to J.A. Van Zijffle), and by NIH grants AI065495 (to C.A. Lowell) and HL51854 and HL81027 (to M.A. Matthey).

Received for publication October 27, 2005, and accepted in revised form April 4, 2006.

Address correspondence to: Mark R. Looney, 505 Parnassus Ave, San Francisco, California 94143-0130, USA. Phone: (415) 476-1079; Fax: (415) 502-2126; E-mail: mark.looney@ucsf.edu.


